This morning Sarepta announced that they posted statistically significant results after a 36-week study on their medication Eteplirsen, a treatment for DMD. Patients were issued doses of Eteplirsen once weekly during the study that ended with a successful 6-minute walk test relative to patients who received placebos. The study was performed at the Nationwide Children’s Hospital in Columbus, Ohio.
David Cornes holds a degree in economics from the University of Montana.